Bortezomib, rituximab, and dexamethason (BORID) is an active salvage regimen for patients with relapsed/refractory mantle cell lymphomaJ. Drach,H. Kaufmann, O. Pichelmayer,V. Sagaster, S. Holzer, C. Zielinski,M. RadererANNALS OF ONCOLOGY(2008)引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要